Skip to main content

Technologies

19 results found
Microfluidics Pharmaceuticals / Nutraceuticals Physics
Technologies
ID: 2019-015 Recombinant human Gal-1 treatment improves membrane repair capacity, increases myogenic markers and decreases inflammation in dysferlin deficient myotubes, providing novel evidence regarding how Gal-1 favorably improves muscle function in LGMD2B.